Gilead Sciences

This early-stage study is testing the safety and how the body handles a new combination HIV drug (B/F/TAF) in full-term newborns who were exposed to HIV at birth. The goal is to see if this drug can be used to prevent the babies from getting infected. The study involves 16 infant…

This study tests a drug called tenofovir alafenamide (TAF) in 150 children and teens with chronic hepatitis B. Half receive TAF and half receive a placebo for 24 weeks. Researchers are checking how safe the drug is, how the body processes it, and whether it lowers virus levels. T…

This study tests whether switching to a new 2-drug combination pill (bictegravir/lenacapavir) is as safe and effective as staying on the standard 3-drug pill (Biktarvy) for people with HIV-1 whose virus is already suppressed. About 577 participants who have been on Biktarvy for a…

This study provides access to the drug bulevirtide (Hepcludex®) for people with chronic hepatitis delta virus infection who have compensated liver disease (with or without cirrhosis). Participants must meet specific health criteria, including a positive HDV RNA test. The goal is …

This study tests a new combination of two HIV drugs, bictegravir and lenacapavir, in children and adolescents aged 2 to 17 with HIV-1. The goal is to see if this once-daily pill is safe and works well enough to replace more complex daily medication routines. About 75 participants…

This study is testing several immunotherapy drug combinations in people with advanced non-small cell lung cancer that has spread. The goal is to see if these combinations can shrink tumors and improve survival. About 400 participants will receive different drug mixes, including d…

This phase 2 study tests several new drug combinations in people with non-small-cell lung cancer. It includes three substudies: one for untreated advanced cancer, one for cancer that has progressed after prior treatment, and one for early-stage cancer that can be surgically remov…

This phase 3 trial tests whether a once-weekly pill (islatravir/lenacapavir) can keep HIV under control as well as daily standard care. About 600 people with HIV who already have undetectable virus levels will switch to the weekly pill or stay on their current daily regimen. The …

This phase 3 trial compares a new targeted drug, sacituzumab govitecan, against the standard chemotherapy docetaxel in 603 people with advanced non-small cell lung cancer that has worsened after prior treatments. The main goal is to see if the new drug helps people live longer. T…

This study is testing the long-term safety of a drug called seladelpar in people with primary biliary cholangitis (PBC), a chronic liver disease. About 340 adults who have taken seladelpar before will receive either 5 mg or 10 mg daily for several years. Researchers will monitor …

This study tests whether people with HIV who are already well-controlled on a daily pill (B/F/TAF) can safely switch to a once-weekly tablet (islatravir/lenacapavir). About 600 participants will take either the weekly pill or continue their daily regimen for 48 weeks. The goal is…

This study tested a drug called sacituzumab govitecan in 227 people whose solid tumors had spread to other parts of the body. The main goal was to see if the drug could shrink tumors. Researchers measured how many patients had their tumors shrink or disappear. This is not a cure,…

This study tests whether a combination of two lab-made antibodies and an antiviral drug called lenacapavir, given every 6 months, can keep HIV under control in adults whose virus is already suppressed by daily pills. About 83 participants will either switch to the new long-acting…

This study looks at how safe and effective certain HIV medicines are for children and teens (ages 4 weeks to under 18 years) who already have the virus under control. Participants take a combination of drugs (atazanavir or darunavir boosted with cobicistat, plus emtricitabine/ten…

This study tests whether a new once-weekly oral combination of two experimental drugs, lepetegravir and lenacapavir pacfosacil, can keep HIV under control as well as the daily pill Biktarvy. About 675 adults with already-suppressed HIV will take either the weekly combo or continu…

This early-phase study tests a new oral drug called GS-9911, alone or with an intravenous immunotherapy (zimberelimab), in 45 adults with advanced solid tumors who have run out of standard options. The main goals are to check safety, find the best dose, and see how the body handl…

This study tests an experimental drug called emvistegrast (GS-1427) in about 228 adults with moderate to severe ulcerative colitis. Participants receive either the drug or a placebo, and researchers check if symptoms improve after 12 weeks. The goal is to see if the drug can redu…

This phase 3 study compares a targeted drug called sacituzumab govitecan against standard chemotherapy in about 623 people with advanced triple-negative breast cancer that does not express PD-L1 (a protein that makes immunotherapy work). Participants either have not received prio…

This study is testing the HIV medication Biktarvy (a combination of three drugs) in adolescents and children who have HIV-1. The goal is to see how the drug works in younger bodies, confirm the right dose, and check for side effects. About 177 participants will take the pill once…

This study tests a new medicine called lenacapavir in people with HIV whose current drugs are no longer working due to multidrug resistance. The drug is given as a pill and an injection, and is added to their failing regimen for 14 days before switching to an optimized background…

This study tests whether adding an experimental drug (domvanalimab) to a standard immunotherapy (zimberelimab) plus chemotherapy works better than the standard immunotherapy plus chemotherapy alone for people with head and neck cancer that has spread or come back. About 100 adult…

This study tests a drug called sacituzumab govitecan combined with pembrolizumab (and sometimes chemotherapy) as a first treatment for people with advanced or metastatic non-small-cell lung cancer that lacks specific genetic changes. About 193 participants will receive these comb…

This phase 3 study tests a drug called sacituzumab govitecan (Trodelvy) against standard chemotherapy in 331 Asian patients with HR+/HER2- metastatic breast cancer who have already tried at least two prior chemotherapies. The goal is to see if the new drug can delay cancer growth…

This study tests a drug called sacituzumab govitecan in 80 Chinese patients with metastatic triple-negative breast cancer who have already tried at least two other treatments. The goal is to see if the drug can shrink tumors or slow the disease. Participants receive the drug intr…

This study tests if a once-weekly combination of two oral drugs, islatravir and lenacapavir, can keep HIV under control in people whose virus is already suppressed. 142 participants switched from their daily HIV pill to this weekly regimen. The main goal is to see if the virus st…

This study tests whether a new combination of two immunotherapy drugs (zimberelimab and domvanalimab) plus chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has not been treated…

This study tested an antiviral drug called tenofovir in children aged 2 to 12 with chronic hepatitis B. The goal was to see if the drug could lower the amount of virus in their blood compared to a placebo. The trial involved 90 children and measured safety and effectiveness over …

This early-stage study tests a new drug called GS-4528, given alone or with another cancer drug (anti-PD-1), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 182 participants will…

This study tests a drug called sacituzumab govitecan against standard chemotherapy in 640 people with endometrial cancer that has come back after platinum-based chemo and immunotherapy. The goal is to see if the new drug can slow cancer growth and help people live longer. Partici…

This early-phase trial is testing a new oral drug called zamzetoclax (GS-9716) in about 145 people with advanced solid tumors. The drug is given alone or combined with standard chemotherapies. The main goals are to find the safest dose and understand side effects. This is a safet…

This study tests a drug called sacituzumab govitecan in 53 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug can shrink tumors. Researchers will also track how long any response lasts and how well the drug contro…

This study follows 170 people with chronic hepatitis D who are taking bulevirtide to see how well it works over time and what side effects may occur. Researchers will track serious liver problems like liver failure, cancer, or need for transplant. The goal is to understand the dr…

This study tests whether people with HIV who are already virally suppressed on complex treatment can safely switch to a simpler two-drug combination of bictegravir and lenacapavir. About 689 participants will be randomly assigned to either switch to the new drugs or stay on their…

This phase 3 study tests whether the drug sacituzumab govitecan (Trodelvy) can help people with a common type of advanced breast cancer (HR+/HER2-) live longer without their cancer growing. About 654 participants will receive either the new drug or one of three standard chemother…

This phase 3 trial tests whether combining sacituzumab govitecan (Trodelvy) with pembrolizumab (Keytruda) works better than standard chemotherapy plus pembrolizumab for people with advanced triple-negative breast cancer that has a protein called PD-L1. About 443 participants who …

This study tests a new shot called lenacapavir, given once a year, to see if it can safely prevent HIV in people at risk. About 350 participants will receive the injection and be monitored for side effects and drug levels. If successful, this could offer a much more convenient op…

This study tests a new option for preventing HIV: a shot given under the skin every 6 months, called lenacapavir. It compares how well people stick with the shot versus taking a daily pill (Truvada). About 268 people at higher risk for HIV will take part. The goal is to see if th…

This phase 3 study tested a daily pill called F/TAF (Descovy) to prevent HIV infection in nearly 5,400 men and transgender women who have sex with men and are at high risk. Participants took either F/TAF or the existing prevention drug Truvada. The goal was to see if F/TAF is as …

This study tested two ways to prevent HIV in over 5,000 adolescent girls and young women at risk. One group received a long-acting shot every six months, while others took daily pills. The goal was to see how well each method works to keep participants HIV-free.

This study aimed to test whether the drug obeldesivir could safely prevent filovirus diseases like Ebola in people who had been exposed. It was designed for adults with known or suspected high-risk contact within the past 21 days. However, the study was withdrawn before enrolling…

This study looks at a new way to prevent HIV in people who inject drugs. It tests a shot given under the skin every 6 months (lenacapavir) and compares it to daily pills. The goal is to see how well the shot works in the body and if it is safe. About 181 people in the US are taki…

This phase 3 trial tests lenacapavir, a long-acting drug given as a shot every six months, to prevent HIV infection. Over 3,200 participants at risk for HIV received either lenacapavir or daily pills. The goal is to see if the shot is as effective as daily PrEP, offering a more c…

This study tests a new long-acting injection called lenacapavir, given every 6 months, to prevent HIV in cisgender women in the US. About 253 women will receive either the injection or daily pills (Truvada) to compare how well the drug works in the body, its safety, and how accep…